Clinical trial No longer in our active list Phase 2 Interventional Ages 50 to 80

Assessing FNP-223 for slowing progression of Progressive Supranuclear Palsy

Official title: A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER)

Run by Ferrer Internacional S.A. · NCT06355531 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing if a new drug called FNP-223 can help slow down the progression of Progressive Supranuclear Palsy in people living with the condition.

More Progressive Supranuclear Palsy trials Research outlook What's coming for Progressive supranuclear palsy: the next 6 months to 5 years

Quick facts

PhasePhase 2
Study typeInterventional
Ages50 Years to 80 Years
SexAll
Enrollment220 (estimated)
SponsorFerrer Internacional S.A.
Industry-sponsored
Locations42 sites (Carlsbad, California and 41 other locations)
Trial IDNCT06355531 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are males and females aged 50 to 80 with a diagnosis of possible or probable PSP-RS and specific clinical features.

Probably not a fit

Patients with advanced PSP symptoms or those residing in skilled nursing facilities may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial evaluates the efficacy and safety of FNP-223 in slowing the progression of Progressive Supranuclear Palsy (PSP) over a 52-week period. Participants will be assessed using the PSP Rating Scale to measure changes in their condition. The study includes both an active treatment group receiving FNP-223 and a placebo group for comparison. The aim is to determine if FNP-223 can effectively slow disease progression in individuals diagnosed with PSP.

Why it matters

Potential benefit: If successful, this treatment could significantly slow the progression of PSP, improving quality of life for patients.

How similar studies have gone: While there have been studies on PSP treatments, the specific approach with FNP-223 is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male or female participants aged 50 to 80 years, inclusive, at the time of informed consent.
* Diagnosis of possible or probable PSP of the Richardson's Syndrome (PSP-RS) phenotypes according to the Movement Disorders Society's Progressive Supranuclear Palsy (MDS PSP) clinical features criteria. At least 1 (either 1 or both) of the following 2 items must be met:

  1. Vertical supranuclear gaze palsy.
  2. Slowing of vertical saccades AND postural instability with falls within the first 3 years of PSP symptoms.
* Presence of PSP symptoms within ≤3 years prior to screening.
* MoCA score ≥23
* Full 28-item PSPRS score ≤40.
* Able to ambulate independently or with minimal assistance defined as the ability to take at least 10 steps (stabilization of 1 arm \[ie, use of cane\]).
* Body weight range ≥43 kg/95 lbs to ≤120 kg/265 lbs.
* Reside outside a skilled nursing facility or dementia care facility, except for participants residing in an assisted living facility.
* Has a caregiver or study partner who will accompany them to the study visits. The caregiver or study partner must be a person who has frequent contact (at least 7 hours per week at 1 time or in different days) with the participant and is able to provide information about the participant's medication and overall condition. Prior to the conduct of any study procedures, the caregiver or study partner must be willing to sign the independent ethics committee (IEC)/institutional review board (IRB) approved informed consent.

Exclusion Criteria:

Non-PSP- RS Movement Disorders or other central nervous system (CNS) Diseases

* Score of 3 on any functional domain in the PSP-CDS.
* Participants with known PSP genetic mutation (based on familiar or clinical history).
* Evidence of other neurological disorder that could explain signs of PSP (eg, Parkinson's disease, Alzheimer disease, etc.).
* Brain magnetic resonance imaging (MRI) within 1 year of screening consistent with:
* Primary degenerative diseases other than PSP.

Procedures

* For the optional substudy only: Contraindication or refusal to undergo 2 lumbar punctures for obtaining CSF.
* Contraindication or inability to tolerate MRI for screening MRI and volumetric brain MRI assessments throughout the substudy.

Where it's running

  • The Neurology Center of Southern California - Carlsbad
    Carlsbad, California, United States
    Recruiting
  • UCSF Weill Institute for Neurosciences
    San Francisco, California, United States
    Recruiting
  • Rocky Mountain Movement Disorders Center
    Denver, Colorado, United States
    Recruiting
  • University of Miami Miller School of Medicine
    Miami, Florida, United States
    Recruiting
  • Augusta University
    Augusta, Georgia, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts, United States
    Recruiting
Show 36 more locations
  • Quest Research Institute
    Farmington Hills, Michigan, United States
    Recruiting
  • Robert & John M. Bendheim Parkinson and Movement Disorders Center at Mount Sinai
    New York, New York, United States
    Recruiting
  • Columbia University Irving Medical Center
    New York, New York, United States
    Recruiting
  • Duke Neurology
    Durham, North Carolina, United States
    Recruiting
  • Vanderbilt University Medical Center
    Nashville, Tennessee, United States
    Recruiting
  • Central Texas Neurology Consultants
    Round Rock, Texas, United States
    Recruiting
  • Groupe Hospitalier Pellegrin
    Bordeaux, France
    Recruiting
  • Hôpital de la Timone
    Marseille, France
    Recruiting
  • L'Hôpital Universitaire Carémeau
    Nîmes, France
    Recruiting
  • Hôpital Universitaire Pitié Salpêtrière
    Paris, France
    Recruiting
  • Hôpital Pierre-Paul Riquet
    Toulouse, France
    Recruiting
  • Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson
    Beelitz, Germany
    Recruiting
  • Universitätsklinikum Düsseldorf
    Düsseldorf, Germany
    Recruiting
  • Universitätsklinikum Leipzig
    Leipzig, Germany
    Recruiting
  • Ludwig-Maximilians-Universität München (LMU)
    Munich, Germany
    Recruiting
  • Pécsi Tudományegyetem Általános Orvostudományi Kar
    Pécs, Hungary
    Recruiting
  • IRCCS Istituto Delle Scienze Neurologiche di Bologna
    Bologna, Italy
    Recruiting
  • Azienda Ospedale Università di Padova
    Padova, Italy
    Recruiting
  • Azienda Ospedaliero-Universitaria Pisana
    Pisa, Italy
    Recruiting
  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - San Raffaele Pisana
    Roma, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria San Giovanni di Dio Ruggi d'Aragona
    Salerno, Italy
    Recruiting
  • Neurologia Śląska Centrum Medyczne
    Katowice, Poland
    Recruiting
  • Mazowiecki Szpital Bródnowski w Warszawie
    Warsaw, Poland
    Recruiting
  • Hospital de Braga
    Braga, Portugal
    Recruiting
  • Campus Neurológico Senior - Torres Vedras
    Torres Vedras, Portugal
    Recruiting
  • Complejo Hospitalario Universitario A Coruña
    A Coruña, Spain
    Recruiting
  • Hospital Germans Trias i Pujol
    Badalona, Spain
    Recruiting
  • Hospital Universitario Cruces
    Barakaldo, Spain
    Recruiting
  • Hospital Clínic de Barcelona
    Barcelona, Spain
    Recruiting
  • Hospital Universitario Ramón y Cajal
    Madrid, Spain
    Recruiting
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
    Recruiting
  • Hospital Universitario de Navarra
    Pamplona, Spain
    Recruiting
  • Hospital Universitario Virgen del Rocío
    Sevilla, Spain
    Recruiting
  • Hospital Universitari i Politècnic La Fe
    Valencia, Spain
    Recruiting
  • University of Cambridge
    Cambridge, United Kingdom
    Recruiting
  • University Hospital Southampton
    Southampton, United Kingdom
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.